Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by Leerink Partnrs to Hold

Leerink Partnrs cut shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a strong-buy rating to a hold rating in a report issued on Friday morning, Zacks.com reports.

Other research analysts have also issued research reports about the company. Royal Bank of Canada reiterated an outperform rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Leerink Partners lowered shares of Agios Pharmaceuticals from an outperform rating to a market perform rating and lowered their target price for the company from $60.00 to $56.00 in a research note on Friday. The Goldman Sachs Group increased their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a neutral rating in a report on Tuesday, June 4th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, StockNews.com lowered shares of Agios Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of Hold and an average price target of $52.50.

Agios Pharmaceuticals Price Performance

AGIO opened at $44.43 on Friday. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $53.28. The stock has a market capitalization of $2.52 billion, a PE ratio of -7.03 and a beta of 0.75. The firm’s fifty day moving average price is $45.61 and its 200 day moving average price is $39.92.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.51) EPS. On average, equities research analysts forecast that Agios Pharmaceuticals will post -4.85 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at $40,000. NEOS Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $210,000. North Star Asset Management Inc. bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $216,000. Finally, XTX Topco Ltd bought a new position in Agios Pharmaceuticals during the second quarter valued at about $230,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.